Abstract
Aims: This study aimed to evaluate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) at the Centre National de Transfusion (CNTS) of Lomé, Togo. Methods: This is a cross-sectional study, which included volunteer blood donors from 2011–2015 at the CNTS of Lomé. The age ranged from 18–60 years old. All donors were screened for HBV, HCV and HIV using ELISA and the seroprevalence of these viruses was calculated using Graph Pad Prism software. Results: Male donors (86.44%) were significantly more represented than female (13.71%). Regular donors (72.2%) were more than first time donors (28%, p<0.001). The overall seroprevalence during the study period was 2.63%, 1.58% and 0.92% for HBV, HCV and HIV, respectively. The seroprevalence of these viruses in blood donors decreased from 2011–2015. The proportion of HBV among blood-borne viral infection represented, 48.81%, 54.16%, 51.71%, 46.71% and 58.10% in 2011, 2012, 2013, 2014 and 2015, respectively. Conclusion: This study permitted to monitor the dynamics of HBV, HCV and HIV in blood donors for five years in Lomé, and revealed the need to reinforce screening, preventive and sensitization strategies to improve transfusion safety in Togo.
Highlights
We present the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) among Togolese blood donors for the period 2011–2015 in National Blood Transfusion Center of Lomé
Blood transfusion is one of the most important therapeutic options of life-saving intervention for recipients who are in diseased or non-diseased conditions with severe blood loss. It is associated with certain risks, which can lead to adverse consequences that may cause acute or delayed complications and bring the risk of transfusion-transmissible infections including HIV, hepatitis B and hepatitis C and syphilis [7,8,9]
This study aimed to evaluate the seroprevalence of HBV, HCV and HIV from 2011–2015
Summary
Transfusion-transmitted infections have been a major concern in transfusion medicine [1]. In the mid 1980s, hepatitis B core antibody (HBc) testing was introduced to screen blood donors in hepatitis B virus (HBV) nonendemic countries [1]. Hepatitis B is one of most common infectious diseases of the world infecting about two billion people of which an estimated 350 million chronically infected cases have been reported so far [4]. Hepatitis C virus infection is another common chronic blood-borne infection with an estimated 3.9 million persons infected with the virus and with a positive correlation with the onset and progression of liver cirrhosis. Infections by hepatitis B virus (HBV) and hepatitis C virus (HCV) cause serious mortality, morbidity as well as financial burden and are a major global health problem [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
